Ulla Hedner (Former)
1 – 15 of 57
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Treating Life-Threatening Bleedings : Development of Recombinant Coagulation Factor VIIa
2017)(
- Book/Report › Book
- 2015
-
Mark
Recombinant activated factor VII: 30 years of research and innovation.
(
- Contribution to journal › Scientific review
- 2014
-
Mark
Joint disease, the hallmark of haemophilia: What issues and challenges remain despite the development of effective therapies?
(
- Contribution to journal › Scientific review
- 2013
-
Mark
Progressive improvement in wound healing with increased therapy in haemophilia B mice
(
- Contribution to journal › Article
- 2012
-
Mark
Factor VIIa binding to endothelial cell protein C receptor: Differences between mouse and human systems
(
- Contribution to journal › Article
-
Mark
Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors
(
- Contribution to journal › Letter
-
Mark
Activated factor VII: my story.
(
- Contribution to journal › Article
-
Mark
FVIIa as therapeutic agent in hemophilia and beyond.
(
- Contribution to journal › Article
-
Mark
Endothelial cell protein C receptor-mediated redistribution and tissue-level accumulation of factor VIIa.
(
- Contribution to journal › Article
-
Mark
Influence of endothelial cell protein C receptor on plasma clearance of factor VIIa.
(
- Contribution to journal › Letter
- 2011
-
Mark
Joint protection in haemophilia
(
- Contribution to journal › Article
-
Mark
Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following IV administration in haemophilia patients.
(
- Contribution to journal › Article
-
Mark
Redistribution and Hemostatic Action of Recombinant Activated Factor VII Associated with Platelets
(
- Contribution to journal › Article
-
Mark
Monitoring rFVIIa 90 μg kg(-1) dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h.
(
- Contribution to journal › Article
-
Mark
Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays.
(
- Contribution to journal › Article